Stock SPAG SPAGO NANOMEDICAL AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Spago Nanomedical AB

Equities

SPAG

SE0004899474

Market Closed - Nasdaq Stockholm
Other stock markets
 11:08:25 2024-05-03 EDT 		5-day change 1st Jan Change
0.341 SEK -4.75% Intraday chart for Spago Nanomedical AB -5.28% +4.28%
04-24 Spago Nanomedical AB Reports Favorable Data in Breast Cancer Model with Tumorad CI
04-16 Spago Nanomedical AB Announces Appointment of Birgitta Rembratt Svensson as Head of CMC & Supply, Effective June 1, 2024 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
SPAGO NANOMEDICAL AB Stock Spago Nanomedical AB
+4.28% 7.09M -
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-16.10% 11.41B
A-
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+67.65% 3.81B
D+
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-30.20% 2.3B
C
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-14.31% 2.16B -
B-
VERACYTE, INC. Stock Veracyte, Inc.
-26.03% 1.56B
C+
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+36.95% 1.19B
B-
SEEGENE, INC. Stock Seegene, Inc.
-2.40% 760M
C+
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-38.57% 444M
C-
CURIOX BIOSYSTEMS CO., LTD Stock Curiox Biosystems Co., Ltd
+13.72% 339M - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. SPAG Stock
  4. Ratings Spago Nanomedical AB